XOMA Corp
$ 39.71
0.25%
17 Apr - close price
- Market Cap 471,982,000 USD
- Current Price $ 39.71
- High / Low $ 40.74 / 39.36
- Stock P/E 27.13
- Book Value 7.07
- EPS 1.46
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.34 %
- 52 Week High 40.67
- 52 Week Low 20.95
About
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Analyst Target Price
$65.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-12 | 2025-08-13 | 2025-05-07 | 2025-03-06 | 2024-11-05 | 2024-08-13 | 2024-05-09 | 2024-03-08 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.26 | 0.7 | 0.44 | 0.0562 | -0.06 | -1.59 | 0.84 | -0.86 | -0.49 | -0.6 | -0.45 | -0.62 |
| Estimated EPS | -0.11 | -0.09 | -0.2 | -0.2725 | -0.3033 | -0.44 | -0.27 | -0.81 | -0.36 | -0.48 | -0.52 | -0.5 |
| Surprise | 0.37 | 0.79 | 0.64 | 0.3287 | 0.2433 | -1.15 | 1.11 | -0.05 | -0.13 | -0.12 | 0.07 | -0.12 |
| Surprise Percentage | 336.3636% | 877.7778% | 320% | 120.6239% | 80.2176% | -261.3636% | 411.1111% | -6.1728% | -36.1111% | -25% | 13.4615% | -24% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XOMA
2026-04-16 18:08:38
This article analyzes Xoma Corporation's (NASDAQ: XOMAP) stock movements and provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. It highlights conflicting sentiment across various time horizons, suggesting choppy conditions, and offers specific entry, target, and stop-loss levels. The report also details multi-timeframe signal analysis indicating support and resistance levels.
2026-04-16 00:39:52
XOMA Royalty Corp's CFO, Jeffrey Trigilio, exercised 4,000 Performance Stock Units (PSUs), converting them into 4,000 common shares. To cover tax obligations, 1,632 shares were withheld through a non-open market transaction at $36.76 per share. Following these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 PSUs.
2026-04-15 11:39:52
XOMA Royalty Corporation (NASDAQ:XOMA) has received an average "Moderate Buy" rating from six brokerages, with an average 12-month price target of $61.60. Despite beating earnings estimates in its last quarter, analysts forecast a negative EPS for the current fiscal year. Institutional investors, including Vanguard, Opaleye, and Woodline, have significantly increased their stakes, now owning 95.92% of the company's stock.
2026-04-14 15:09:18
XOMA Corp's 8.375% DP PFD B (XOMAO) has declared a dividend of $0.5234, maintaining its previous dividend. The ex-dividend date is May 14, 2024, with the payment date scheduled for May 30, 2024.
2026-04-14 09:09:18
The article states that Turnstone Biologics is set to be acquired by XOMA Royalty. No further details about the acquisition or the companies involved are provided.
2026-04-13 13:54:00
This article provides an AI-driven analysis of Xoma Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ: XOMAO), highlighting a neutral near-term sentiment with a mid-channel oscillation pattern. It outlines three distinct trading strategies—position trading, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, and strong risk-reward short setup for potential downside.
